



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rodríguez Aguirre *et al.*

Application No. 10/551,887

Filed: September 30, 2005

Confirmation No.

For: WHOLE EMPTY VIRAL PARTICLES OF
THE INFECTIOUS BURSAL DISEASE
VIRUS (IBDV), PRODUCTION PROCESS
AND APPLICATIONS

Examiner:

Art Unit:

Attorney Reference No. 7572-73331-01

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed May 26, 2006

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- Information Disclosure Statement
 - Form 1449
 - References (21)
- The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Gwynedd Warren, Ph.D.
Registration No. 45,200

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rodríguez Aguirre *et al.***Application No. 10/551,887****Filed:** September 30, 2005**Confirmation No.**

For: WHOLE EMPTY VIRAL PARTICLES OF
THE INFECTIOUS BURSAL DISEASE
VIRUS (IBDV), PRODUCTION PROCESS
AND APPLICATIONS

Examiner:**Art Unit:****Attorney Reference No.** 7572-73331-01

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed May 26, 2006

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.


Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Gwynedd Warren, Ph.D.
Registration No. 45,200

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	7572-73331-01
		Application Number	10/551,887
		Filing Date	September 30, 2005
		First Named Inventor	Rodríguez Aguirre
		Art Unit	
		Examiner Name	

MAY 30 2006
PATENT & TRADEMARK OFFICE
U.S. PATENT AND TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.


Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		6,458,362	October 1, 2002	CASAL <i>et al.</i>
		6,602,705	August 5, 2003	BARNETT <i>et al.</i>

OTHER DOCUMENTS

	BOTTCHER <i>et al.</i> , "Three-dimensional structure of infectious bursal disease virus determined by electron cryomicroscopy," <i>J. Virol.</i> , 71:325-330, 1997.
	BIRGHAN <i>et al.</i> , "A non-canonical Ion proteinase lacking the ATPase domain employs the Ser-Lys catalytic dyad to exercise broad control over the life cycle of a double-stranded RNA virus," <i>Embo J.</i> , 19:114-123, 2000.
	CASTÓN <i>et al.</i> , "C terminus of infectious bursal disease virus major capsid protein VP2 is involved in definition of the t number for capsid assembly," <i>J. Virol.</i> , 75:10815-10828, 2001.
	CHEVALIER <i>et al.</i> , "The maturation process of pVP2 requires assembly of infectious bursal disease virus capsids," <i>J. Virol.</i> , 76:2384-2392, 2002.
	DA COSTA <i>et al.</i> , "The capsid of infectious bursal disease virus contains several small peptides arising from the maturation process of pVP2," <i>J. Virol.</i> , 76:2393-2402, 2002.
	FERNÁNDEZ-ARIAS <i>et al.</i> , "Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles," <i>J. Gen. Virol.</i> , 79:1047-1054, 1998.
	FERNÁNDEZ-ARIAS <i>et al.</i> , "The major antigenic protein of infectious bursal disease virus, VP2, is an apoptotic inducer," <i>J. Gen. Virol.</i> , 71:8014-8018, 1997.
	KADONO-OKUDA <i>et al.</i> , "Baculovirus-mediated production of the human growth hormone in larvae of the silkworm, <i>Bombyx mori</i> ." <i>Biochem. Biophys. Res. Commun.</i> , 213:389-396, 1995.
	KIBENGE <i>et al.</i> , "Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells," <i>Can. J. Vet. Res.</i> , 63:49-55, 1999.
	KOCHAN <i>et al.</i> , "Characterization of the RNA binding activity of VP3, a major structural protein of IBDV," <i>Archives of Virology</i> , 148:723-744, 2003.
	LEUSCH <i>et al.</i> , "A novel host-vector system for direct selection of recombinant baculoviruses (bacmids) in <i>Escherichia coli</i> ," <i>Gene</i> , 160:191-194, 1995.

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 	Attorney Docket Number	7572-73331-01
	Application Number	10/551,887
	Filing Date	September 30, 2005
	First Named Inventor	Rodríguez Aguirre
	Art Unit	
	Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patente
		LOMBARDO <i>et al.</i> , "VP1, the putative RNA-dependent RNA polymerase of infectious bursal disease virus, forms complexes with the capsid protein VP3, leading to efficient encapsidation into virus-like particles," <i>J. Virol.</i> , 73:6973-6983, 1999.		
		LOMBARDO <i>et al.</i> , "VP5, the nonstructural polypeptide of infectious bursal disease virus, accumulates within the host plasma membrane and induces cell lysis," <i>Virology</i> , 277:345-357, 2000.		
		LUCKOW <i>et al.</i> , "Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in <i>Escherichia coli</i> ," <i>J. Virol.</i> , 67:4566-4579, 1993.		
		MARAVER <i>et al.</i> , "Identification and molecular characterization of the RNA polymerase-binding motif of the inner capsid protein VP3 of infectious bursal disease virus," <i>J. Virol.</i> , 77:2459-2468, 2003.		
		MARTÍNEZ-TORRECUADRADA, J.L., "Different architectures in the assembly of infectious bursal disease virus capsid protein expressed in insect cells," <i>Virology</i> , 278:322-331, 2000.		
		SÁNCHEZ, A.B. and RODRÍGUEZ, J.F., "Proteolytic processing in infectious bursal disease virus: identification of the polyprotein cleavage sites by site-directed mutagenesis," <i>Virology</i> , 262:190-199, 1999.		
		SHARMA <i>et al.</i> , "Infectious bursal disease virus of chickens: pathogenesis and immunosuppression," <i>Developmental and Comparative Immunology</i> , 24:223-235, 2000.		
		TACKEN <i>et al.</i> , "Interactions in vivo between the proteins of infectious bursal disease virus: capsid protein VP3 interacts with the RNA-dependent RNA polymerase, VP1," <i>J. Gen. Virol.</i> , 81(1):209-218, 2000.		
		VAKHARIA, V.N., "Development of recombinant vaccines against infectious bursal disease," <i>Biotechnology Annual Review</i> , 3:151-168, 1997.		
		VAN DEN BERG <i>et al.</i> , "Infectious bursal disease (Gumboro disease)," <i>Rev. Sci. Tech.</i> , 19:527-543, 2000.		

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.